Integrating molecular diagnostics into anticancer drug discovery

被引：0

作者：

István Peták

Richárd Schwab

László Őrfi

László Kopper

György Kéri

机构：

[1] István Peták is at KPS Medical Biotechnology and Healthcare Services Ltd,and the Ist Department of Pathology and Experimental Cancer Research

[2] 5 Ribary,and the Department of Pharmaceutical Chemistry

[3] 1022 Budapest,László Kopper is at the Ist Department of Pathology and Experimental Cancer Research

[4] Hungary,Department of Medical Chemistry and Pathobiochemistry

[5] Semmelweis University,undefined

[6] 26 Üllői út,undefined

[7] 1085 Budapest,undefined

[8] Hungary.,undefined

[9] Richárd Schwab is at KPS Medical Biotechnology and Healthcare Services Ltd,undefined

[10] 5 Ribary,undefined

[11] 1022 Budapest,undefined

[12] Hungary.,undefined

[13] László Őrfi is at Vichem Chemie Research Ltd,undefined

[14] Budapest,undefined

[15] Hungary,undefined

[16] Semmelweis University,undefined

[17] Högyes E. u. 9.,undefined

[18] 1092 Budapest,undefined

[19] Hungary.,undefined

[20] Semmelweis University,undefined

[21] 26 Üllői út,undefined

[22] 1085 Budapest,undefined

[23] Hungary.,undefined

[24] György Kéri is at Vichem Chemie Research Ltd,undefined

[25] Budapest,undefined

[26] Hungary,undefined

[27] and the Pathobiochemistry Research Group of the Hungarian Academy of Sciences,undefined

[28] Semmelweis University,undefined

[29] Budapest,undefined

[30] H-1085,undefined

[31] Hungary.,undefined

来源：

Nature Reviews Drug Discovery | 2010年 / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Efforts to repeat the success of pioneering molecularly targeted cancer drugs, such as trastuzumab, for particular patient populations have been hampered by factors such as a lack of correlation between the molecular markers used to select patients for treatment and the drug response. This article highlights lessons learned from the development of drugs targeting members of the epidermal growth factor receptor family, and discusses strategies to decrease the risk of failure in clinical trials by more effectively integrating molecular diagnostics into anticancer drug discovery and development.

引用

页码：523 / 535

页数：12

共 50 条

[1] Integrating molecular diagnostics into anticancer drug discovery
Petak, Istvan
Schwab, Richard
Orfi, Laszlo
Kopper, Laszlo
Keri, Gyorgy
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) : 523 - 535
[2] Molecular Biology and Anticancer Drug Discovery
Lazo, John S.
MOLECULAR BIOLOGY OF CANCER: TRANSLATION TO THE CLINIC, 2010, 95 : 9 - 29
[3] Anticancer drug discovery aided by molecular movies
不详
FUTURE MEDICINAL CHEMISTRY, 2012, 4 (15) : 1879 - 1879
[4] Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care
Ross, JS
Ginsburg, GS
DRUG DISCOVERY TODAY, 2002, 7 (16) : 859 - 864
[5] Editorial: Molecular targets for anticancer drug discovery and development
Ntwasa, Monde
Dlamini, Zodwa
FRONTIERS IN GENETICS, 2024, 15
[6] Molecular targets for novel anticancer drug discovery - Preface
Buolamwini, JK
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04)
[7] ANTICANCER DRUG DISCOVERY
SIKIC, BI
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) : 738 - 740
[8] Plants in Anticancer Drug Discovery: From Molecular Mechanism to Chemoprevention
Siddiqui, Arif Jamal
Jahan, Sadaf
Singh, Ritu
Saxena, Juhi
Ashraf, Syed Amir
Khan, Andleeb
Choudhary, Ranjay Kumar
Balakrishnan, Santhanaraj
Badraoui, Riadh
Bardakci, Fevzi
Adnan, Mohd
BIOMED RESEARCH INTERNATIONAL, 2022, 2022
[9] Cell cycle molecular targets in novel anticancer drug discovery
Buolamwini, JK
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) : 379 - 392
[10] Diagnostics and drug discovery products
不详
BIOTECHNOLOGY LAW REPORT, 2003, 22 (02) : 121 - 121

← 1 2 3 4 5 →